CAN Press Kit
Contraceptive Accelerator Network (CAN) is an agile pharmaceutical company committed to accelerating the development of the next generation contraceptives for sperm-producers.
Introduction
Contraceptive Accelerator Network is a for-profit subsidiary of Male Contraceptive Initiative (MCI), a private non-profit foundation that provides funding and advocacy support for non-hormonal, reversible male contraception research and development.
CAN was established as a small, mission-centric pharmaceutical company with the specific intent of ensuring that promising non-hormonal, reversible contraceptive targets receive the support necessary to develop them as next generation birth control methods delivered to those who produce sperm.
CAN’s vision is “Progress Accelerated” and its mission is to achieve reproductive autonomy for all by accelerating research and development of non-hormonal, reversible contraceptives.
MCI/CAN System Map
Organizational Overview
Contraceptive Accelerator Network works in parallel with Male Contraceptive Initiative to identify appropriate programs to support through the testing and evaluation processes required prior to Investigational New Drug (IND)-enabling studies and clinical trials. As necessary, CAN will continue clinical development to ensure its programs continually move through the drug development process.
The company’s operations are streamlined and intentionally designed to maximize cost and time efficiencies in all activities. This allows CAN to take advantage of the many drug discovery resources commercially available to increase its impact while reducing overhead costs and allowing for an expanded portfolio of projects as and when appropriate.
Founded in December 2021, the company has already raised over $1 million in funding to support promising male contraceptive targets.
Project Profile
Triptonide is a natural compound originally derived from Tripterygium Wilfordii Hook F that has displayed reversible male contraceptive effects in both mice and monkeys.
A single daily oral dose of it has shown to induce deformed sperm with minimal or no forward motility and, consequently, male infertility. This effect has also been shown to wear off in a matter of weeks after animal models ceased consuming the compound.
This indicates that there is significant potential for Triptonide to be a natural, reversible, non-hormonal contraceptive targeting sperm.
Tripterygium Wilfordii Hook F
Staff & Board
Michael Rusnak
President & Executive Manager
Heather Vahdat
Chief Strategy Officer
Logan Nickels, PhD
Chief Science Officer
Kevin Shane
Vice President of Marketing & Operations
Board of Directors
Connie Moreadith, Board Member, Public Health Consultant
Susan Rich, Board Member, Principal at Alafiya Consulting Services in Public Health and Philanthropy
Michael Rusnak, Board Member, President & Executive Manager at Contraceptive Accelerator Network
Contact
Feel free to contact us with any questions!
Email
contact@contraceptionforall.com
Phone
+1 (828) 484-1788